Platforms for synthesis and testing of emerging and zoonotic viruses
新兴病毒和人畜共患病毒的合成和测试平台
基本信息
- 批准号:8375872
- 负责人:
- 金额:$ 54.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAttenuatedBioinformaticsBiological ModelsBioterrorismCategoriesChiropteraClinicalComputer SimulationCoronavirusCultured CellsDatabasesDeletion MutationDevelopmentDistantEngineeringEpidemicEpithelial CellsFerretsFrequenciesFutureGenetic TranscriptionGenomeGoalsGrowthHumanHuman VirusIn VitroInterferonsInterventionKineticsMapsMissionModelingMolecular BiologyMovementMusMutationOrganismPathogenesisPharmaceutical PreparationsPhenotypePhylogenetic AnalysisPolyproteinsProteinsPublic HealthRecombinantsRecoveryRoleSARS coronavirusSourceSubgroupSystemTestingTransgenic MiceVaccinesVariantViralVirulenceVirusVirus ReceptorsViverridaeagedattenuationbiodefensecoronavirus spike glycoproteindesignengineering designhuman coronavirushuman diseasein vivomouse modelnovel viruspandemic diseasepathogenpreventprogramsreceptorrecombinational repairreconstructionreplicaseresponsesenescencestructural biologysynthetic biologytooltransmission process
项目摘要
There has been an increase in recognized trans-species movement and human disease from zoonotic
viruses, as well as increased concern about intentional design and introduction of zoonotic organisms in
bioterrorism. Our ability to respond to such emerging zoonotic-human viruses has been limited by our
inability to predict the source, frequency, and mechanisms of virus host-species switching and adaptation.
Recent advances in bioinformatics, molecular biology, structural biology, and synthetic biology, provide tools
to design, synthetically reconstruct, and test new and emerging pathogens from sequence databases alone.
However, development of broadly-applicable platforms strategies for emerging viruses has not occurred, in
part due to concerns about possible misuse of synthetic biology and engineered host-range variants. We
propose that is an essential mission of the RCEs to demonstrate the safe use and potential of synthetic
biology in rapid response platforms. SARS-coronavirus (SARS-CoV) is a category C emerging pathogen that
caused severe human disease worldwide. SARS-CoV is proposed to have emerged in humans following
trans-species movement of Bat-Coronaviruses (Bat-CoV) that have been identified by sequence but have
not been grown in culture. This proposal uses SARS-CoV and zoonotic Bat-CoV to establish platforms for
recovery and testing of zoonotic viruses. The proposed program is comprised of four integrated Specific
Aims that will design and synthetically reconstruct distinct serogroups of zoonotic bat-CoV from sequence
databases, and define the determinants of host-species movement and adaptation in culture, and in young
and senescent mouse models. Further, the Aims will develop strategies for stable and universal attenuation
of pathogenesis of all coronavirus groups. The established approaches will allow rapid response and control
of natural and deliberately designed human coronaviruses, and also will be directly applicable to
development of similar specific rapid-response systems for recovery, analysis, attenuation and response to
other category A, B, or C emerging pathogens of concern for human disease or bioterrorism.
从人畜共患病到公认的跨物种迁移和人类疾病的增加,
病毒,以及对故意设计和引进人畜共患病生物体的日益关注,
生物恐怖主义我们应对这种新出现的人畜共患病病毒的能力受到了我们的限制。
无法预测病毒宿主物种转换和适应的来源、频率和机制。
生物信息学、分子生物学、结构生物学和合成生物学的最新进展,
设计,综合重建,并测试新的和新兴的病原体从序列数据库单独。
然而,针对新兴病毒的广泛适用的平台策略的开发尚未发生,
部分原因是担心可能滥用合成生物学和工程宿主范围变体。我们
我建议,RCE的一项基本使命是证明合成药物的安全使用和潜力,
快速反应平台中的生物学。SARS冠状病毒(SARS-CoV)是一种C类新兴病原体,
在世界范围内引发了严重的人类疾病。SARS-CoV被认为是在人类中出现的,
蝙蝠冠状病毒(Bat-CoV)的跨物种移动,已通过序列鉴定,但
没有在文化中成长。该提案利用SARS-CoV和人畜共患蝙蝠冠状病毒建立平台,
人畜共患病病毒的回收和检测。该计划由四个具体的综合方案组成。
目的从序列设计和综合重建人畜共患蝙蝠冠状病毒的不同血清群
数据库,并定义了宿主种运动和适应文化的决定因素,并在年轻的
和衰老小鼠模型。此外,这些目标将制定稳定和普遍减毒的战略
所有冠状病毒组的发病机制。既定的方法将允许快速反应和控制
自然和故意设计的人类冠状病毒,也将直接适用于
开发类似的特定快速响应系统,用于恢复、分析、衰减和响应
其他A、B或C类新出现的人类疾病或生物恐怖主义病原体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark R Denison其他文献
Mark R Denison的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark R Denison', 18)}}的其他基金
Inhibitors of Coronavirus Fidelity and Cap Methylation as Broadly Applicable
冠状病毒保真度和帽甲基化抑制剂广泛适用
- 批准号:
9217551 - 财政年份:2014
- 资助金额:
$ 54.55万 - 项目类别:
Platforms for synthesis and testing of emerging and zoonotic viruses
新兴病毒和人畜共患病毒的合成和测试平台
- 批准号:
8234184 - 财政年份:2011
- 资助金额:
$ 54.55万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 54.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 54.55万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 54.55万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 54.55万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 54.55万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 54.55万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 54.55万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 54.55万 - 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 54.55万 - 项目类别:
Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 54.55万 - 项目类别:
Research Grant














{{item.name}}会员




